Immunade Microbiome Therapy
“Instead of starting with a health problem and trying to find a solution, why not start with a solution and see what health problems it can solve.”
John Hare, Developer of Hyper-Egg Technology and Immunade Microbiome Therapy
Immunade is the Human adaptation of our Animal Health Veterinary Biologic, used to prevent diarrhea in young animals caused by E. Coli bacteria. Our processing technique allows it to also maintain its natural passive immunity and the natural antimicrobial enzyme, Lysozyme.
Immunade is a solution looking for a problem.
What is Microbiome Therapy?
The gut microbiota consists of some 100 trillion mostly good and bad bacteria, normally coexisting in harmony. This number is about 10 times the number of cells in the human body, with 100 times the number of human genes. It has also been found that while all humans are genetically 99.99% the same, our gut microbiota is likely only 10-30% the same. And likely the reason we are all so different.
Recent research has shown that how goes these bugs, goes your health, with many studies showing the relationship of the gut microbiota to almost all human health disorders. In other words, “Keep your bugs happy and they'll keep you healthy.”
Microbiome Dysbiosis (MD) is when your bugs are not happy, or in scientific terms, the bad bacteria overgrow and cause problems.
The simplest form of MD is the bacterial infection involved in Traveler's Diarrhea, where an overgrowth of usually E. Coli bacteria produces a toxin that causes inflammation, resulting in digestive upset and diarrhea.
With Immunade, we hypothesize that many health disorders are caused by Microbiome Dysbiosis. If we can prevent this bad bug overgrowth, we can prevent the disorder. And since our individual gut microbiomes are only 10-30% the same, maybe we'll only have success with that portion of the population. A breakthrough if the disorder in question is life threatening.
Our intention is to do citizen scientist funded studies with suitable subjects for various health disorders.
For more information please see www.immunade.com
Clostridium Difficile Antibody
The Super-bug Clostridium Difficile is a gram positive, spore forming bacteria known primarily for causing antibiotic associated diarrhea in patients admitted to hospitals and residents of health care facilities. The rate of incidence and severity of C. diff infections (CDI) has risen, annually affecting between 1 – 3 million people in North America and Europe. In severe cases, symptoms include pseudo membranous colitis, bowel perforation, and death. About 30,000 deaths annually in the USA are linked to CDI (CDC report: January 2015), with over 90% of these being patients 65 years of age or older. CDI is responsible for more deaths than all other intestinal infections combined.
Current medical treatment constitutes the use of certain antibiotics at a cost of between $2,000 and $16,000 per patient. C. Diff however has proven resistant as the current therapy has failed to cure about 25-30% of patients and new strains have evolved with increasing resistance and higher virulence. With aging populations rising in both North America and European countries, increasing placements in acute care and long-term care environments and continued widespread use of antibiotics, Clostridium Difficile Infection presents a growing threat to public health. A new, effective treatment will represent a huge advance in medical science, where the annual health care cost of this disease in the United States alone is estimated at over $3 Billion.
In pursuit of the project goals, we have already accomplished the following:
- Tested the effectiveness of C. Diff antibodies in laboratory studies.
- Tested the effectiveness of C. Diff antibodies in piglets with C. Diff infections.
- Proved effectiveness of antibody therapy in proof of concept clinical studies in patients with C. Diff infections in collaboration with Gastroenterologists from Australia, the United States and Canada and demonstrated positive clinical response.
- Developed appropriate clinical development plan and budget.
- Received approval from Health Canada for commencement of phase 2 clinical trials.
- Initiated contact with clinicians to commence clinical trials.
- Submitted patent applications in the U. S. A., Canada and Europe (U.S patent approved 11/02/17).